Depression in late life by Barry, D. Lebowitz
Despite its prevalence and seriousness, depression
in late life remains underappreciated as a source
of disability and suffering for older people and
their families. Despite a solid and substantial body
of research, recognition of depression remains
problematic and is often attributed to normal
developmental changes in aging. Treatment effi-
cacy data notwithstanding, the adequacy and
appropriateness of treatment is highly variable.
This paper contains a broad overview of new
research developments in depression in late life
and the disabilities associated with it. Serving as
an introduction to the specific papers that follow
in this issue of Dialogues in Clinical Neuroscience,
this article scans the knowledge base in basic, clin-
ical, and health services research, identifying the
highlights of current work in the area and propos-
ing areas of needed expansion of research efforts. 
hree factors combine to make depression in
late life a primary concern in worldwide public health.
First, the global population is growing older, gaining
nearly 30 years of life expectancy in this century.
1 Sec-
ond, our appreciation of the disabling consequences of
depression has been underscored by the landmark
report of the World Health Organization on the “global
burden of disease.”
2 Third, the tools of contemporary
neuroscience have significantly enhanced our under-
standing of the pathophysiologic and etiologic mecha-
nisms of depression.
3-7
Depression in older people is a significant public health
problem.
8 It is the cause of unnecessary suffering for
those whose illness is unrecognized or inadequately
treated, and it burdens families and institutions provid-
ing care for the elderly.Because of the stereotypic notion
that older people are necessarily beset by many physical
illnesses and social and economic problems, clinicians,
family members,and older people themselves often con-
clude that depression is a normal condition of late life.
Clinically, the symptom of depressed mood may be less
commonly reported than a variety of somatic complaints,
sleep and appetite change, and general loss of interest.
9
These factors combine to make diagnosis and treatment
of depression highly variable and problematic.
10 
This paper,and the other papers in this issue,will demon-
strate that depression in older people is widespread and
serious, and that the comorbidity of depression with
other illnesses is particularly significant. Moreover, we
will show that depression can be diagnosed in the older
patient and that it can be differentiated from normal
aging. Importantly, a variety of treatments have been
demonstrated to be safe and efficacious in the elderly,
and long-term treatment might be indicated.
Onset and course of depression
Depression in late life is a very heterogeneous condi-
tion.Onset may be early in life with the course recurrent
from a first episode earlier in adulthood,or the onset of
the first episode may be late in life.In general,compared
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with patients of the same age with recurrent depression,
those patients with the first onset of depression in late
life are likely to have a less satisfactory response to
treatment and a more chronic course.
There are significant brain changes in depression:
frontal and temporal lobe atrophy,
11,12 periventricular
and subcortical deep white matter hyperintensities,
13 and
significantly decreased metabolism in a variety of brain
regions (dorsolateral prefrontal cortex, inferior frontal
cortex,basal ganglia).
14 Many of these changes are asso-
ciated with normal aging as well.Late-onset depression
often is associated with a variety of brain abnormalities,
such as ventriculomegaly and white matter hyperinten-
sities, and with cognitive impairments. Recent research
has uncovered important sources of clinical and biolog-
ical heterogeneity within late-life–onset depression,and
subgroups with distinctive patterns of clinical presenta-
tions, course, mechanisms, and outcomes have been
identified.
15-17
The association between depression and cognitive
impairment has been well established, though the
direction of causality has been disputed, as has the
methodology of assessment.
18,19 There does seem to be
general agreement, however, that late-life depression
with cognitive impairment that is reversed by antide-
pressant treatment is,more often than not,a predictor
of the development of an irreversible dementia such as
Alzheimer's disease or vascular dementia.
20
Converging findings implicate vascular disease in the
pathogenesis of one particular subgroup. Geriatric
depression is often comorbid with vascular disorders
and is accompanied by lesions in the basal ganglia and
prefrontal areas of the brain. The clinical profile of
depression in patients with vascular disease is often
characterized by motor retardation, lack of insight, and
impairment of executive functions.This clinical presen-
tation suggests that dysfunction of frontal brain systems
is a possible contributing factor to depression in late
life.
21-24 It also suggests that treatment for cerebrovascu-
lar disease may have preventive implications for late-
life–onset depression.The article by Alexopoulos and
colleagues in this issue of Dialogues in Clinical Neuro-
science addresses this specific topic.
Comorbidity and disability
Depression coexisting with physical illness has been
shown to increase levels of functional disability,increase
the use of health care resources,reduce the effectiveness
of rehabilitation in older patients with stroke, Parkin-
son's disease,heart disease,pulmonary disease,and frac-
tures,and increase risk of death.
25,26 Depression has been
shown to exert a strong and independent effect on func-
tional disability.That effect is independent of diagnosis
or overall medical burden. Functional disability itself
predicts the development of depression and, converse-
ly, depressive symptomatology is a risk factor for the
onset or progression of disability.
27-30 Studies have shown
that treatment for depression is safe and effective in
patients with complex patterns of comorbidity,and sug-
gest that treatment for depression can reduce excessive
levels of disability and result in improved levels of func-
tioning.
31
Studies of the psychosocial and medical correlates of
late-life depression have also suggested possible mech-
anisms for the development of depression in older per-
sons.There is substantial ongoing research on the cen-
tral nervous system effects of the cytokines,particularly
interleukin-1β ,in cortisol production,inflammation,and
immune system activation.It is hypothesized that these
mechanisms may be involved in the physiological and
behavioral responses to illness and the genesis of
depression.
25 The article by Katz in this issue of Dia-
logues in Clinical Neuroscience specifically examines
this topic.
Subsyndromal depression in the elderly
Evidence is mounting to support the notion that clini-
cally significant depression is a spectrum disorder
rather than a categorical disease entity.While recent
studies report a 1% to 2% prevalence of major depres-
sion and a 2% prevalence of dysthymia among com-
munity-dwelling elderly, much higher rates (13% to
27%) are observed in this age group for subsyndromal
depressions.
32,33 Subsyndromal depressions are levels of
depressive symptoms (referred to as subsyndromal,
subclinical,or symptomatic depression) that are associ-
ated with increased risk of major depression, physical
disability,medical illness,and high use of health services
but that do not meet the Diagnostic and Statistical Man-
ual of Mental Disorders 4 edition (DSM-IV) criteria for
major depression or dysthymia.
34 In medically ill elder-
ly and nursing home residents, the prevalence of such
symptom levels may be as high as 50%.
35The course of
subsyndromal depressions is variable, but in the con-text of severe physical disability, from stroke, for
example, the depressive symptomatology can be per-
sistent over extended periods of time.
36,37 Ongoing
research is actively pursuing questions of treatment
response in subsyndromal depressions and whether
interventions can have more generalized benefits on
functional disability, quality of life, and needs for
health care.
37
Gender and hormonal issues
One of the most striking and consistent findings in psy-
chiatric epidemiology is that women have higher rates
of all types of depression than men.Increases in depres-
sion have been observed among women during natural
or surgical menopause and in response to antiestrogen
therapy for breast cancer.Though still under debate,
symptoms attributed to menopause-related changes in
mid-life women include: depressed mood; decreased
self-confidence; difficulty making decisions; anxiety;
insomnia and fatigue; problems in memory and con-
centration; and decreased libido.
38 Hormone replace-
ment therapy has been associated with improvements
in mood and quality of life, but the data are still very
preliminary.
Despite claims in the popular media, there is no evi-
dence supporting the antidepressant effects of the
androgens testosterone and dehydroepiandosterone
(DHEA) in either men or women.
39 The data on hor-
monal factors in the development and treatment of
depression remain preliminary, with some suggestive
leads for further study.
40A more detailed understanding
of these interactions,
41 and prospective clinical trials,will
be needed to determine whether manipulation of estro-
gen and other sex steroids has a significant role in the
treatment of depression in late life.
Treatment issues
The goals of treatment are to achieve remission of
symptoms,prevent relapse and recurrence,and improve
the quality of life and functional capacity.
Pharmacotherapy
In general, the older tricyclic antidepressants (TCAs)
and the newer selective serotonin reuptake inhibitors
(SSRIs) have comparable efficacy in elderly patients.
The newer drugs of mixed action have not been exten-
sively studied in the elderly.The SSRIs are coming to be
seen as preferable largely because of ease of use, less
dosage adjustment, different side effect profiles includ-
ing a reduced anticholinergic and cardiovascular bur-
den,and greater acceptance.
42,43The article by Schneider
in this issue of Dialogues in Clinical Neuroscience specif-
ically addresses this topic. It is uncertain whether this
conclusion applies to clinically important subgroups
such as those patients with chronic and very severe lev-
els of major depression,or to very old patients.
Side effects
As in younger adults, the elderly tend to tolerate the
SSRIs better than TCAs.This is based on fewer anti-
cholinergic effects, little or no adverse effects on cogni-
tion at recommended doses, and minimal cardiovascu-
lar effects.Common complaints linked to SSRIs include
nausea, diarrhea, insomnia, headache, agitation, and
anxiety. Side effects of SSRIs that may be relatively
more common or more problematic in older patients
include SSRI-induced syndrome of inappropriate anti-
diuretic hormone secretion (SIADH), extrapyramidal
symptoms,and bradycardia.
26 Based on available data,it
is not possible to determine whether the elderly are
more sensitive to these more frequent side effects than
younger populations. It should be noted that SSRIs are
metabolized in the liver and inhibit the drug-metaboliz-
ing enzyme cytochrome P450, the route through which
many other medications commonly taken by older peo-
ple are metabolized.Such drugs include β -blockers,class
Ic antiarrhythmics, and benzodiazepines.The combina-
tion of drugs may result in clinically significant alter-
ations in drug concentration levels or in complex drug
interactions.
44-46
Psychotherapy
Research has clearly demonstrated the efficacy of stan-
dardized approaches to treatment, such as cognitive-
behavioral therapy, interpersonal therapy, and prob-
lem-solving therapy, both alone and in combination
with pharmacotherapy.
47 No single standardized
approach to psychosocial treatment has a consistent
advantage.
48-50 Psychotherapy is a powerful component
of long-term treatment strategies where the contribu-
tion of therapy alone has been shown to provide sub-
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free from depression.
47 Psychotherapy also has partic-
ular utility in older patients who cannot or will not tol-
erate medication, or who are dealing with obviously
stressful situations, interpersonal difficulties, or low
degrees of social support.
Electroconvulsive therapy
Electroconvulsive therapy (ECT) remains an impor-
tant,safe,and efficacious approach to the acute treat-
ment of depression in older patients.
51,52 ECT is par-
ticularly useful in older patients whose medical
condition is so fragile that they cannot tolerate phar-
macotherapy, or in patients who are so acutely suici-
dal that a rapid response is required.ECT is also com-
monly used with patients who have not responded to
pharmacotherapy and for patients with psychotic
depression. Relapse rates following ECT are very
high, however.
53 Important research is now investi-
gating the longer-term efficacy of continuation phar-
macotherapy and continuation ECT to address the
problem of relapse.
Long-term treatment 
Evidence has also continued to accumulate on the
necessity for long-term treatment in late-life
depression. Indeed, older patients with recurrent
depression may need antidepressant treatment
indefinitely to remain well. Moreover, long-term
treatment should be of the same type and same
intensity as that which was successful in the initial,
acute phase. This is in contrast to much prevailing
practice; longitudinal data demonstrate that the
intensity of antidepressant treatment typically
decreases prematurely, prior to 8 weeks of recov-
ery.
54 The appropriate intensity for maintenance reg-
imens using psychotherapy only has not been sys-
tematically studied. Treatment response and
long-term outcome for older patients are generally
similar to those observed in mid-life adults, but the
temporal course may be somewhat slower in the
elderly and the risk of relapse somewhat greater.
55
These differences are especially pronounced in
patients over the age of 70.
56 The article by Schnei-
der in this issue of Dialogues in Clinical Neuro-
science is devoted to issues in treatment.
Health care service and resource use
In mixed age samples, major depression leads to exces-
sive utilization of medical services and greater health
care costs.In nursing homes and among high utilizers of
medical services, patients with depression incur signifi-
cant increases in direct costs for medical care.
57-60
Longitudinal data demonstrate that depressive symp-
tomatology in elderly primary care patients is associ-
ated with increased physician visits, medication use,
emergency room visits, and outpatient charges.
61,62
Among medical inpatients,major depression has been
associated with increased utilization of health care
resources, including longer hospital stays and greater
mortality, for example, in those undergoing elective
coronary artery bypass grafting.
63-65 After discharge,
depression accounts for a substantial increase in ambu-
latory health care use.
66
The general health care sector is by far the principal
source of treatment for older persons with depression.
Recently analyzed data from the 1987 National Med-
ical Expenditure Survey show that over 55% of older
persons using mental health care received this care
from general physicians. In contrast, less than 3% of
individuals over age 65 report having received outpa-
tient treatment from mental health professionals, a
proportion lower than that for any other adult age
group.
67
The scope and responsibility of primary care providers
are being expanded and redefined in many health care
systems. Primary care providers are charged with
greater responsibility for diagnosis,treatment,and long-
term management in all areas of health care, including
care of older patients with mental disorders.That being
the case, older people may derive substantial benefit
from increased sensitivity to identification of depression
on the part of their primary care physicians. Interven-
tions directed toward improvement, recognition, and
treatment,however,have not necessarily translated into
added benefit when compared to practice as usual in the
primary care setting.
68-70
Suicide and late-life depression
Suicide rates increase with age in most countries of the
world, and men outnumber women suicide completers
by a substantial amount. Recent studies of completed
suicide have reinforced the close association with major
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60depressive illness, especially in the elderly.
71,72 With
increased age, the relative importance of the contribu-
tion of depression to suicide risk is magnified.The typi-
cal clinical profile of the older suicide completer is late-
onset, nonpsychotic, unipolar depression of moderate
severity uncomplicated by substance abuse or personal-
ity disorder.
Tragically, the depression in these older people was
rarely recognized or treated.The failure to recognize
and treat depression was not due to restricted access to
care.A majority of these depressed suicide victims had
seen a health care provider in the last month of life,
39% in the last week, and 20% on the day of suicide.
73
The article by Bruce and Pearson in this issue of Dia-
logues in Clinical Neuroscience examines this topic.
Future directions
Practice-relevant intervention studies
The rich and valuable literature on treatment of depres-
sion in late life has not been as informative for practice
as it might be. In particular, we do not know why treat-
ments rarely work as well in practice as they do in clin-
ical trials, whether treatment enhances functioning,
whether early treatment predicts a more favorable
response, how can we keep people well once they have
been made well, or the approaches that should be used
for the treatment-resistant patient.
These issues are raised within the context of what has
been called a public health model of treatment.
74 We
cannot yet address these as well as we would like,how-
ever,largely because the direction and culture of treat-
ment research has been determined by a more narrow-
ly defined regulatory model
75 geared to the approval
and registration of pharmacologic agents.This regula-
tory model has been the dominant force shaping treat-
ment research.
In general,the rigid exclusions of most regulatory-ori-
ented clinical trials have significantly distorted the con-
clusions of these studies.Age itself is the most common
concern, with most studies being restricted, to all
intents and purposes,to the “young-old”population of
patients in their sixties. Few older patients have ever
been studied
76 despite the clear impact of advanced age
on pharmacokinetics,dynamics,and drug metabolism
46
and on treatment response.
56 Geriatric treatment
research protocols have simply taken mid-life adult
protocols and substituted a different age-range while
keeping the remainder of the study unchanged with
respect to eligibility,dosing,duration of treatment,and
instrumentation.
Studies that are informed by a public health model are
often called “effectiveness studies.”Public health stud-
ies bring research into the world of actual practice with
time-pressured clinicians taking care of large numbers
of patients with uncertain clinical presentations, com-
plex comorbidities, varying degrees of interference,
and with ideal levels of compliance.The exclusive focus
on symptomatology is expanded to include outcomes
related to issues of function,disability,morbidity,mor-
tality,resource use,and quality of life.The classic pub-
lic health trial is used to assess the expected outcome
under usual circumstances of practice.
In contrast to the elegantly crafted efficacy trial, a
public health trial must be bigger in size, simpler in
design, broader in terms of inclusions, and narrower
in terms of exclusions, and more representative with
respect to settings of care.These settings will not be
limited to academic health centers or tertiary care
institutions,but will include primary care,community
settings, and long-term care institutions. Unlike effi-
cacy trials where specially trained clinicians carry out
state-of-the-art assessment and treatment, public
health trials are carried out in settings of usual prac-
tice where there is a broad and variable range of clin-
ician expertise and experience with the disorder
under study. Outcome measures will necessarily
extend beyond symptomatology to include function,
disability, morbidity, mortality, health care and other
resource use, family burden, institutionalization, and
quality of life.
Development of preventive interventions
Given the breadth and depth of the knowledge base
regarding depression in late life, a clear opportunity is
now presented to mount an initiative directed toward
prevention. Prevention has many aspects.An interven-
tion may be based on models of pathophysiology or eti-
ology to prevent onset of the illness.Vascular depression
presents one such opportunity, as does the research on
bereavement
77-79 and a variety of comorbidities, such as
vision or hearing loss and other illnesses.In the context
of treatment, preventive interventions may well be
Depression in late life - Lebowitz Dialogues in Clinical Neuroscience - Vol 1 . No.2 . 1999
61directed at relapse, recurrence, or excessive levels of
functional disability.
Safety and consumer protection
As part of a public health mission,we must also attend
to issues of safety and consumer protection. For exam-
ple, the widespread use of over-the-counter, unregu-
lated treatments needs to be carefully examined for
possible benefit and for potential harm. Use of com-
plementary and alternative approaches is very high
and growing.
80,81 Even in patients volunteering for par-
ticipation in clinical drug trials, use of herbal medica-
tions is substantial; in a series of 150 such subjects,
82
56% reported having used herbs in the last month.It is
therefore incumbent upon us to evaluate these treat-
ments including natural products such as St John’s
Wort or kava, psychophysiologic approaches such as
eye movement desensitization reprocessing (EMDR),
and somatic approaches such as acupuncture, if for no
other reason than that our patients are using these in
large, uncontrolled, natural experiments.
Dissemination
A final priority must be dissemination.Our patients are
not helped by treatments that are available in only in
scientific journals.A recent example highlights the prob-
lem. Lehman and Steinwachs
83 report that fewer than
half the patients with schizophrenia in the United States
received a level of care that was consistent with the cur-
rent state of the art.This is an important finding that
cannot be ignored.As a field we must take on the chal-
lenge of translating our research into practice and plac-
ing the most powerful clinical tools in the hands of
patients, their families, and the clinicians that take care
of them.The Geriatric Psychiatry Alliance initiatives on
depression
84 represent an important and potentially
valuable approach to this problem.
Conclusions
There has been significant progress in our understand-
ing of the nature, clinical course, and treatment of
depression in late life.Important findings have emerged
in a number of areas directly affecting clinical care and
have,in turn,stimulated further research.These findings
include: the association of late-onset depression with
brain abnormalities and vascular disease; the mutual
reinforcement of depression and functional disability;
the clinical importance of subsyndromal states;the pos-
sible role of sex steroids; the clinical utility of new anti-
depressant treatments, including the SSRIs and stan-
dardized psychotherapies; the need for long-term
treatment; the importance of depression in the general
health care system; and the clear relationship between
depression and suicide. New opportunities have
emerged for research in a more public-health–oriented
model,in prevention,and in dissemination.
Depression remains a central concern to older people,
their families,and the clinicians who take care of them.
Even when it appears to be an understandable
response to illness, the onset of depression should be
viewed as a sentinel event that increases the risk for
subsequent declines in health status and functional
ability. Early recognition, diagnosis, and initiation of
treatment of depression in older persons present
opportunities for improvements in quality of life, the
prevention of suffering or premature death, and the
maintenance of optimal levels of function and inde-
pendence for older people. ❏
Sections of this paper represents an expansion of material originally pub-
lished in the Journal of the American Medical Association (Lebowitz et al,
1997) and in the Annual Review of Gerontology and Geriatrics (Lebowitz
and Harris, in press). 
State of the art
62REFERENCES
1. Lebowitz, BD, Pearson JL, Cohen GD. Older Americans and their illnesses.
In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 3rd edition. Balti-
more, Md: Williams and Wilkins; 1998;3-20.
2. Murray CJL, Lopez AD, eds. The Global Burden of Disease. Cambridge,
Mass: Harvard University Press; 1996.
3. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of
depression. Arch Gen Psychiatry. 1997;54:597-606.
4. Kumar A, Jin Z, Bilker W, Udupa J, Gottlieb G. Late-onset minor and
major depression: early evidence for common neuroanatomical substrates
detected by using MRI. Proc Natl Acad Sci USA. 1998;95:7654-7658.
5. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life
depression, and Alzheimer’s disease: the emerging role of functional imag-
ing. Neuropsychopharmacology. 1998;18:407-430.
6. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to
cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psy-
chiatry. 1998;55:580-592.
7. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hip-
pocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA.
1996;93:3908-3913.
8. Diagnosis and Treatment of Depression in Late Life. NIH Consens Dev Conf
Consens Statement 1991;9(3):Nov 4-6.
9. Gallo JJ, Anthony JC, Muthen BG. Age differences in the symptoms of
depression: a latent trait analysis. J Gerontol Psychol Sci. 1994;49:P251-P264.
10. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of
depression in late life: consensus statement update. JAMA. 1997;278:1186-1190.
11. Coffey CE, Wilkinson WE, Weiner RD, et al. Quantitative cerebral
anatomy in depression: a controlled magnetic resonance imaging study.
Arch Gen Psychiatry. 1993;50:7-16.
12. Ketter TA, George MS, Kimbrell TA, et al. Functional brain imaging,
limbic function and affective disorders. Neuroscientist. 1996;2:55-65.
13. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex
abnormalities in mood disorders. Nature. 1997;386:824-827.
14. Kennedy SH, Javanmard M, Vaccarino FJ. A review of functional neu-
roimaging in mood disorders: positron emission tomography and depres-
sion. Can J Psychiatry. 1997;42:467-475.
15. Kumar A, Miller D, Ewbank D, et al. Quantitative anatomic measures
and comorbid medical illness in late-life major depression. Am J Geriatr Psy-
chiatry. 1997;5:15-25.
16.  Alexopoulos GS, Young RC, Shindeckler R. Brain computed tomography
in geriatric depression and primary degenerative dementia. Biol Psychiatry.
1992;31:591-599.
17.  Krishnan KRR, Gadde KM. The pathophysiologic basis for late-life
depression: imaging studies of the aging brain. Am J Geriatr Psychiatry.
1996;4(suppl 1):S22-S33.
18. Bassuck SS, Berkman LF, Wypij D. Depressive symptomatology and inci-
dent cognitive decline in an elderly community sample. Arch Gen Psychiatry.
1998;55:1073-1081.
19. Meyers BS, Bruce ML. The depression-dementia conundrum: integrating clin-
ical and epidemiological perspectives. Arch Gen Psychiatry. 1998;55:1082-1083.
Depression in late life - Lebowitz Dialogues in Clinical Neuroscience - Vol 1 . No.2 . 1999
63
Depresion en sujetos de edad avanzada
A pesar de su alta prevalencia y de su gravedad, la
depresión en los estadios avanzados de la vida con-
tinúa siendo menospreciada. Ella causa incapacidad
sufrimiento en los sujetos de edad avanzada y en su
entorno familiar.Aunque hay sólidos y sustanciales
datos que provienen de la investigación, el
reconocimiento de la depresión continúa siendo un
problema y se la considera todavía como una
adaptación normal al envejecimiento.Aunque existen
datos sobre la eficacia de su tratamiento,la adecuación
y especificidad de éste es altamente variable. Este
artículo entrega una visión general de los últimos
desarrollos de la investigación en el campo de la depre-
sión en estadios avanzados de la vida y de las inca-
pacidades que ella conlleva. Este artículo sirve de
introducción a los termas específicos de este número
de Dialogues in Clinical Neuroscience y revisa los
aspectos más importantes de la investigación básica y
clínica, como también la atención que ofrecen los ser-
vicios de salud. Se identifican los aspectos más rele-
vantes del trabajo actual en esta área y se proponen las
vías necesarias para extender los esfuerzos en futuras
investigaciones
La dépression du sujet âgé
En dépit de sa fréquence et de sa gravité,la dépression
du sujet âgé reste sous-estimée en tant que  source d’in-
capacité et de souffrance,autant pour le sujet concerné
que pour son entourage.Malgré des données solides et
substantielles fournies par la recherche, la reconnais-
sance de la dépression demeure problématique, au
point qu’elle est souvent attribuée aux conséquences
physiologiques du vieillissement. Malgré l’efficacité
démontrée du traitement,l’adéquation et l’opportunité
de celui-ci sont des plus variables. Cet article donne
une large vue d’ensemble sur les nouvelles voies de
recherche qui gravitent autour de la dépression du sujet
âgé, mais aussi sur les handicaps qui lui sont associés.
Il sert d’introduction aux articles plus spécifiques qui
suivent dans ce numéro de Dialogues in Clinical Neu-
roscience,en examinant les connaissances de base dans
des domaines de recherche aussi divers que les sciences
fondamentales, la clinique et les services de santé. Il
souligne aussi les phénomènes les plus marquants dans
les travaux en cours et propose des voies qui devraient
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